Biotechnology · Los Angeles, California, United States
$5.10
-5.20% (-$0.28)2026-07-08
Smart-Money SignalNeutral · 53/100— Insider open-market flow is flat over 90 days
Net Income-$115.3M
EPS$-3.16
Market Cap$187.2K
Price Performance
Historical data including institutional events
Company Profile
D
Deborah Birx
CEO & Executive Director
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology. The companyâs product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
